Navigation Links
Fetal tissue-derived stem cells may be ideal source for repairing tissues and organs
Date:8/22/2013

Putnam Valley, NY. (Aug 22 2013) Multipotent fetal dermal cells (MFDCs) may be an ideal source for cell therapy for repairing damaged tissues and organs. Their performance is superior to that of adult dermal cells, said a research team in Italy that developed a cell isolation technique for MFDCs and subsequently published a study that appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct1022chinnici.

"When compared to adult dermal cells, fetal cells display several advantages, including a greater cellular yield after isolation, the ability to proliferate longer, and the retention of differentiation potential," said study co-author Dr. C.M. Chinnici of the Fondazie Ri.MED, Regenerative Medicine and Biomedical Technologies Unit in Palermo, Italy. "Cells from fetal dermis have been proven safe and efficacious in the treatment of pediatric burns, but proper characterization of these cells has not yet been provided."

Their research provided a protocol for the isolation and expansion of large numbers of MFDCs that may see future clinical use, said the study authors.

"We generated, propagated and analyzed a proliferating population of cells derived from human fetal dermis taken at 20-22 weeks of gestation," wrote the researchers. "The non-enzymatic isolation technique allows for a spontaneous selection of cells with higher motility and yields a nearly homogeneous cell population."

The MFDCs, they reported, were "highly proliferative and were successfully expanded with no growth factor additions." They noted that, unlike mensenchymal stem cells, which progressively lose their differentiation capacity, the MFDCs "retained their osteogenenic and adipogenic differentiation potential" meaning that their potential impact for cell transplantation is likely to be greater.

"The MFDCs demonstrated their favorable characteristics for a potential large scale production aimed at clinical use," said Dr. Chinnici.

The researchers noted that the most interesting aspect of their study was the finding that multipotent cells can be successfully isolated from small fetal skin biopsies and maintained in culture for long periods with multipotency, stability and low immunogenicity retained, "thus generating large quantities of cells for clinical use."

"Given these results, the future prospect is to translate the concept of MFDCs as cells of therapeutic interest into experimental models of tissue regeneration," they concluded.


'/>"/>

Contact: Bob Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Study finds Western diet detrimental to fetal hippocampal tissue transplants
2. Fetal exposure to PVC plastic chemical linked to obesity in offspring
3. Pandemic vaccination did not increase risk of fetal death
4. Signaling pathway linked to fetal alcohol risk
5. New genetic link found between normal fetal growth and cancer
6. Fetal neuromaturation associated with mothers exposure to ddt and other environmental contaminants
7. CWRU dental researchers NIDCR grant targets oral bacteria and fetal death link
8. New protocol developed to decontaminate human fetal tissues used for cell transplantation
9. Fetal programming of sweet tastes elicited pleasure
10. Fetal stress disrupts the way genes are transmitted
11. Fetal stem cell transplantation favorably impacts radiation-induced cognitive dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology: